GP531

About ViCardia Therapeutics

ViCardia Therapeutics is a private, clinical-stage biotech company targeting the significant unmet need in Acute Decompensated Heart Failure (ADHF), where no acute therapy has been shown to reduce mortality risk. The company's approach centers on correcting mitochondrial dysfunction, a fundamental driver of heart failure progression, using its lead compound GP531, a potent AMPK agonist. ViCardia is preparing to advance GP531 into Phase 2 clinical trials, aiming to restore myocardial bioenergetics and improve cardiac contractility. The company is led by a team with extensive cardiovascular research and development experience.

Therapeutic Areas